Stock Analiz

ZeroStack Corp. ZSTK

Other Pharmaceuticals · IPO 2021 · data as of November 13, 2026

$2.74Market cap $60M
Open the interactive analysis →

ZeroStack Corp. (ZSTK) is a healthcare company listed in the US with a market value of about $60M. In the twelve months to June 30, 2026 it had revenue of $40M and net income of -$178M, a net margin of -444.2%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (2/5); the weakest is future growth (0/5).

Key numbers: 5-year revenue growth of 220% a year, a 5-year average ROIC of -151%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 26% above the current price.

About ZeroStack

ZeroStack is listed in the US and classified in other pharmaceuticals, IPO year 2021. Revenue went from $106000 in 2020 to $36M in 2025, growth of about 220.2% a year. It was profitable in 0 of the last 6 years in our data.

Score: 1.0 / 5

Value1/5
Future growth0/5
Track record1/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.5
P/B4.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-9.4%
Shareholder yield0.0%
Intrinsic value vs. price+26%

Growth and quality

Revenue growth (1 yr)-0.5%
Revenue growth (5 yrs, per year)220.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-169.9%
ROIC (5-yr avg.)-151.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$40M$36M$36M$76M$33M$9M$106000
Net income-$178M-$120M-$16M-$57M-$52M-$21M-$14M
Free cash flow-$6M-$9M-$5M-$9M-$17M-$25M-$8M
EPS (diluted)$-43.65$-5.49$-0.73$-2.61$-2.40$-0.98$-0.66
Net margin-444.2%-335.6%-44.4%-75.0%-156.9%-237.9%-13522.6%
ROIC—-98.2%-74.9%-482.9%-75.7%-24.1%-88.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $11.00, 301% above the current price; targets range from $11.00 to $11.00; the consensus rating is “none”; expected EPS is $-4.02 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is ZeroStack stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 26% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does ZeroStack pay a dividend?

Not currently.

Is ZeroStack a good stock to buy?

We do not give buy or sell advice. ZeroStack scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.